



Distribution and Function of Prostaglandin E₂ Receptors in Mouse Uterus: Translational Value for Human Reproduction

DOI:

[10.1124/jpet.119.263509](https://doi.org/10.1124/jpet.119.263509)

Document Version

Final published version

[Link to publication record in Manchester Research Explorer](#)

Citation for published version (APA):

Fischer, D. P., Griffiths, A. L., Lui, S., Sabar, U. J., Farrar, D., O'donovan, P. J., Woodward, D. F., & Marshall, K. M. (2020). Distribution and Function of Prostaglandin E₂ Receptors in Mouse Uterus: Translational Value for Human Reproduction. *Journal of Pharmacology and Experimental Therapeutics*, 373(3), 381-390. <https://doi.org/10.1124/jpet.119.263509>

Published in:

Journal of Pharmacology and Experimental Therapeutics

Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact uml.scholarlycommunications@manchester.ac.uk providing relevant details, so we can investigate your claim.



Distribution and Function of Prostaglandin E₂ Receptors in Mouse Uterus: Translational Value for Human Reproduction¹

Deborah P. Fischer,¹ Anna L. Griffiths,¹ Sylvia Lui, Uzmah J. Sabar, Diane Farrar, Peter J. O'Donovan, David F. Woodward, and Kay M. Marshall

Division of Pharmacy and Optometry, School of Health Sciences (D.P.F., K.M.M.) and Division of Developmental Biology and Medicine, School of Medical Sciences (S.L.), Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom; School of Pharmacy, University of Bradford, Bradford, West Yorkshire, United Kingdom (A.L.G., U.J.S.); Bradford Institute for Health Research, Bradford Royal Infirmary, Duckworth Lane, Bradford, West Yorkshire, United Kingdom (D.F.); Obstetrics and Gynaecological Oncology, Yorkshire Clinic, Bradford Road, Bingley, West Yorkshire, United Kingdom (P.J.D.); Department of Bioengineering, Imperial College London, London, United Kingdom (D.F.W.); and JeniVision Inc., Irvine, California, USA (D.F.W.).

Received October 30, 2019; accepted March 10, 2020

ABSTRACT

Prostaglandin (PG) E analogs are used clinically to ripen the cervix and induce labor. However, selective receptor agonists may have potential to improve induction response rates or manage unwanted uterine hypercontractility in conditions such as dysmenorrhea and preterm labor. To characterize their therapeutic value, PGE₂ analogs were used to investigate the functional E-type prostanoid (EP) receptor population in isolated human uterus. Responsiveness in mouse tissues was also examined to validate its use as a preclinical model. Uterine samples were obtained from mice at dioestrus ($n = 12$), term gestation ($n = 14$), and labor ($n = 12$) and from the lower uterus of women undergoing hysterectomy ($n = 12$) or Caesarean section ($n = 18$). Vehicle and agonist effects were assessed using superfusion and immersion techniques. PGE₂ evoked predominant excitatory responses in mouse and relaxation in human tissues. Selective EP₄ agonists inhibited tissue activity in both nonpregnant species, while the EP₂ mimetic CP533536 also

attenuated uterine contractions throughout gestation. The uterotonic effects of the EP_{3/1} agonist sulprostone were more pronounced than the EP₁ agonist ONO-D1-004, corresponding to abundant EP₃ receptor expression in all samples. The contractile phenotype in mouse compared with human uteri may relate to regional differences as well as high expression of EP₃ receptor transcripts. Similarities in nonpregnant and gestational tissues across species suggest that EP₃ may represent a valuable translational drug target for preventing uterine hypercontractility by employing a selective antagonist.

SIGNIFICANCE STATEMENT

This research validates the use of nonpregnant mice for preclinical drug discovery of uterine EP receptor targets. To determine the utility of novel drugs and delivery systems at term pregnancy and labor, pharmacological agents interacting with EP₃ receptors have clear translational value.

Introduction


Series two prostaglandins (PGs) consist of PGD₂, PGE₂, PGF_{2 α} , prostacyclin, and thromboxane A₂. PGE₂ exhibits a wide spectrum of physiological and pathological functions in various cells and tissues (Coleman et al., 1994; Sugimoto and Narumiya, 2007) and exerts these effects primarily via four EP receptor subtypes. EP₁ and EP₃ receptors produce smooth muscle contraction. The EP₁ receptor mediates this response through an increase in intracellular calcium (Ca²⁺), while activation of the EP₃ receptor predominantly inhibits smooth muscle relaxation through a decrease in adenylyl cyclase. In contrast, EP₂ and EP₄ receptors mediate uterine

quiescence through the intracellular adenylyl cyclase and cAMP pathway (Sugimoto and Narumiya, 2007). EP₁, EP₂, EP₃, and EP₄ have all been isolated and cloned in the mouse (Sugimoto et al., 1992; Honda et al., 1993; Watabe et al., 1993; Nishigaki et al., 1995), revealing the presence of multiple splice variants for EP₃ in mice (Sugimoto and Narumiya, 2007) and humans (Matsuoka and Narumiya, 2007) that are evolutionally conserved (Hla, 2005). Their pleiotropic effects are regulated by receptor expression, constitutive activity, signal transduction pathways, and agonist-induced desensitization (Sugimoto and Narumiya, 2007; Markovič et al., 2017) that differ in health and disease.

PGE₂ mediates reproductive processes, including ovulation, fertilization, implantation, luteolysis, and uterine contractility (Challis et al., 2002; Valdes et al., 2009). In women, total PG concentrations increase at labor compared with term pregnancy (Durn et al., 2010), with a concurrent rise in

¹D.P.F. and A.L.G. contributed equally.

<https://doi.org/10.1124/jpet.119.263509>

 This article has supplemental material available at jpet.aspetjournals.org.

intrauterine and amniotic fluid PGE₂ release throughout parturition (Lee et al., 2008; Durn et al., 2010). A switch in the activator protein family of transcription factors regulates amniotic PGE₂ synthesis and promotes uterine contraction (Lu et al., 2019). Cervical ripening and induction of labor with vaginal, intracervical, or oral PGE₂ are recommended to safely expedite neonatal delivery (NICE, 2008; Vogel et al., 2017; Sheibani et al., 2018; Zhao et al., 2019) and reduce stillbirth rates (Hedegaard et al., 2014). However, aberrant PGE₂ output and an imbalance in EP gene receptor expression are associated with *in vitro* fertilization failure (Ruan et al., 2012) preterm labor (Calder, 1990; Gouveia-Figueira et al., 2017) and a lack of response to labor induction (Konopka et al., 2015). Impaired ovulation, fertility, and decreased litter size were displayed in EP₂-deficient mice (Hizaki et al., 1999; Kennedy et al., 1999; Tilley et al., 1999). However, the physiological role of each EP subtype in regulating uterine contraction is not well defined.

The aim of this study was to characterize functional EP receptors as potential therapeutic targets in uterine tissues using highly selective agonists. Their temporal and regional expression was examined in the isolated mouse uterus during the oestrous cycle, at term gestation (day 18), and during labor. It was hypothesized that predominant excitatory EP_{1/3} receptors in the fundus and EP_{2/4} subtypes in the lower uterus would facilitate caudal contractions for menses and parturition. Efficacy was compared with uterine tissues from non-pregnant and term pregnant women to determine whether the mouse is a suitable system for investigating human uterine biology and pregnancy complications.

Materials and Methods

Experiments on Isolated Mouse Uterine Tissue. Nonpregnant and pregnant female sexually mature Bankin Kingman White (BKW) mice (B & K Universal Ltd., Hull, UK) housed in groups were used throughout this study. All experimental procedures and animal care were carried out at the University of Bradford in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health, the amended Animals Scientific Procedures Act, UK 2012, and ARRIVE guidelines. The animals had free access to food and water and were exposed to a 12-hour light/12-hour dark cycle. Animals used in gestational studies were mated in a harem of three females to one male. The presence of a vaginal plug was observed as evidence of pregnancy; the day of plug detection was termed day 1 of gestation. The mice were weighed regularly to monitor the progression of pregnancy.

The mice were humanely killed by cervical dislocation when non-pregnant ($n = 12$), at day 18 of gestation ($n = 14$), or during labor (one to two pups delivered; $n = 12$). The uterus was dissected from the body, and uterine samples were taken from different anatomic segments along the length of each uterine horn (Griffiths et al., 2006). In nonpregnant animals, the stage of the oestrous cycle was determined by microscopic examination of the vaginal lavage (McLean et al., 2012). In the pregnant and laboring mice, the fetuses were carefully removed from the uterus and were sacrificed by carbon dioxide inhalation.

Uterine samples were immediately set up for superfusion as previously described (Griffiths et al., 2006). In brief, the strips were attached to isometric force transducers under a resting tension of 2 g, and aerated Krebs' solution (95% O₂/5% CO₂) was driven through heating coils (37°C) at a rate of 2 ml/minute (Griffiths et al., 2006). The isolated uterine samples were equilibrated for 30 minutes before the start of drug treatments.

In uterine tissue samples from nonpregnant animals and those taken at late gestation, spontaneous activity diminished after 30 minutes. It was, therefore, difficult to examine the inhibitory effects of the agonists. The inclusion of 5-hydroxytryptamine (5-HT) at 10⁻⁶ M to the perfusate reservoir, which enhances acetylcholine and Ca²⁺ release (Griffiths, 2007), produced uniform, regular myogenicity, allowing the inhibitory properties of the compounds to be explored. Tissue taken during labor displayed a sustained level of activity, so 5-HT was not included in the reservoir for these strips.

PGE₂ and the following selective EP agonists were used: ONO-D1-004, a selective EP₁ agonist (Oka et al., 2003); the selective EP₂ agonists butaprost (Gardiner, 1986) and CP533536 (Li et al., 2003; Paralkar et al., 2003); sulprostone, an EP₁ and EP₃ receptor agonist (Schaaf et al., 1981); and the EP₄ agonists lactam derivative of 8-aza-11-deoxy-PGE₁ (LAC-PGE) (Elworthy et al., 2004) and L-902688 (Billot et al., 2003). They were directly administered into the superfusate as 10 μl bolus doses (10⁻¹¹–10⁻⁷ mol) at 10-minute intervals or until baseline activity had resumed. Agonists were administered immediately after a spontaneous contraction to avoid superimposing responses on background activity; this did not apply if there was no background activity present. Time-matched vehicle controls were also assigned, and only one dose-response curve was performed per tissue. At the end of each experiment, the Krebs' superfusate was replaced with distilled water (Popat and Crankshaw, 2001); this induced a reference contraction (hypotonic shock) that was unique to each tissue strip.

Experiments on Isolated Human Uterine Tissue. Lower segment myometrial biopsies were obtained from premenopausal women undergoing hysterectomy for benign disorders, such as fibroids, pelvic pain, and heavy menstrual bleeding (aged 26–44; follicular stage; $n = 12$). At the time of surgery, none of the donors were using oral contraceptives or had received any hormone therapy. Segments of the upper margin of lower uterine muscle were also obtained at Caesarean section from healthy term pregnant women (aged 22–38; 37–40 weeks) not in labor ($n = 10$) or during active labor (regular contractions, cervical dilation 3–8.5 cm; $n = 8$). Indications included previous Caesarean section ($n = 12$), breech presentation ($n = 2$), fetal distress ($n = 2$), and prolonged labor ($n = 2$), none of which influenced *in vitro* phasic contractions (data not shown). Women who were taking regular prescription medication, who were with multiple fetuses, or who were associated with any major complication of pregnancy, such as hypertension, pre-eclampsia, and diabetes, were excluded from this study. Uterine specimens were obtained from the Yorkshire Clinic, Bradford, and Bradford Royal Infirmary; all women provided informed written consent prior to surgery. Ethical approval for all studies was obtained from the National Research Ethics Committee (LREC: 07/H1306/98).

Human uterine samples were prepared for immersion within an hour of collection as previously described (Fischer et al., 2008). In brief, myometrial strips (10 × 2 × 3 mm), trimmed of endometrial, serosal, fat, and fibrous tissue, were set up in organ baths containing oxygenated Krebs' solution (95% O₂, 5% CO₂, 37°C) and attached to isometric force transducers under a resting tension of 2 g (Senior et al., 1991; Senior et al., 1993). Tissues from nonpregnant and term pregnant donors were equilibrated for at least 90 and 120 minutes, respectively, or until regular phasic contractions had developed. Vehicle and cumulative concentration-effect curves for PGE₂ and EP agonists (10⁻¹⁰–10⁻⁵ M) were added at 30-minute intervals, and only one treatment was assigned per tissue. Responses were expressed as a percentage of hypotonic shock, induced by displacing the Krebs' solution with distilled water (Popat and Crankshaw, 2001).

Measurement of Responses. Uterine activity was measured via isometric force transducers (Grass Instruments Inc., RI, USA) linked to PowerLab hardware (AD Instruments Ltd., Dunedin, New Zealand). PowerLab was connected to a PC, and Chart 5 for Windows (AD Instruments Ltd., Dunedin, New Zealand) was used to display the changes in tissue tension. The integrated area under the curve was measured for 5 and 30 minutes after drug administration for mouse

(Griffiths et al., 2006) and human (Fischer et al., 2008) tissues, respectively, and was expressed as a percentage of the hypotonic shock reference contraction. Superfusion was suitable for highly contractile mouse tissues (measured as moles within the Krebs' superfusate), whereas the immersion technique better suited slow phasic human myometrial activity (measured as Molar in a defined 8 ml organ bath volume). Both are commonly used comparable methods for receptor characterization (Hillock and Crankshaw, 1999; Popat and Crankshaw, 2001; Duckworth et al., 2002; Griffiths et al., 2006; Fischer et al., 2008).

Real-Time Reverse-Transcription Polymerase Chain Reaction Analysis. Total RNA was extracted from snap frozen mouse uterine tissues using TRIzol reagent (Invitrogen Life Technologies, Paisley, UK) followed by the mirVana miRNA isolation Kit (Thermo Fisher Scientific, Waltham, MA) according to the manufacturers' instructions. RNA (1 µg) was converted into cDNA (QuantiTect Reverse Transcription kit; Qiagen, Manchester, UK), and gene expression of β -actin (NM_007393), glyceraldehyde-3-phosphate (GAPDH; NM_008084), EP₁ (NM_013641), EP₂ (NM_008964), EP₃ (NM_011196), and EP₄ receptors (NM_001136079) in uteri from nonpregnant, pregnant, and laboring mice were quantified by real-time reverse-transcription polymerase chain reaction (qRT-PCR). The probes for each gene (Qiagen, Manchester, UK) were used in combination with the QuantiTect SYBR Green Supermix (Qiagen, Manchester, UK) on a Quantstudio 12K flex real-time PCR system (Applied Biosystems, Paisley, UK). Absolute gene transcription was normalized to β -actin and GAPDH, and the relative values compared with internal controls shown.

Statistical Analysis. Data were first tested for normality using a Shapiro-Wilk test. Changes in contractile activity and gene expression were determined using two-way ANOVA with Tukey's *post hoc* test (GraphPad Prism 8.0 software; San Diego, CA). Where data were nonparametric, a Friedman's two-way ANOVA with *post hoc* test was performed (SPSS version 22; NY). A probability of $P < 0.05$ was considered to be significant.

Compounds. 5-HT was obtained from Sigma Aldrich Chemical Co. (Poole, Dorset, UK). Butaprost, PGE₂, and sulprostone were obtained from Cayman Chemicals (distributed by Alexis Corporation (UK) Ltd., Bingham, Notts, UK). LAC-PGE (7-2-[(E)-3-hydroxy-4-(3-trifluoromethyl-phenyl)-phenyl]-but-1-enyl]-5-oxo-pyrrolidin-1-yl-heptanoic acid), CP533536, ONO-D1-004, and L-902688 were received from Allergan Inc. (Irvine, CA, USA) as gifts. Stock solutions of 10⁻² M were prepared by dissolving the compounds in ethanol. Further dilutions were made with 0.9% (w/v) normal saline. The Krebs' solution (pH 7.4) was freshly prepared at the following composition (mM): NaCl 118.9; KCl 4.7; KH₂PO₄ 1.2; MgSO₄ 1.2; and CaCl₂ 2.5, NaHCO₃ 25.0, and glucose 10.0, oxygenated with 95% O₂ and 5% CO₂.

Results

Effect of PGE₂ on Myometrial Activity. In all murine tissues, PGE₂ evoked a dose-dependent excitation curve. In both upper (Fig. 1A) and lower (Fig. 1B) uterine segments, a greater excitatory response to PGE₂ was observed in tissues taken during gestation compared with dioestrus ($P < 0.05$ to $P < 0.001$). Preliminary studies showed that this PGE₂ effect was similar in tissues taken throughout the oestrous cycle (Supplemental Fig. 1). With PGE₂ at 10⁻¹¹ mol, lower segment tissue taken at labor exhibited a greater contractile response than tissue taken on day 18 of gestation ($P < 0.05$). When responses to PGE₂ in lower and upper tissue segments were compared at each gestational stage, no significant regional variation was observed along the length of the uterine horns.

Human lower segment myometrial strips exhibited strong spontaneous contractions when taken during the follicular phase and at term pregnancy before labor. In these tissues, PGE₂ caused predominant utero-relaxant effects (10⁻¹⁰–10⁻⁶ M), with tissue activity partially restored at 10⁻⁵ M (Fig. 2). Spontaneous contractions approximately halved during labor. PGE₂ fully inhibited this myogenicity in a monophasic concentration-related manner by suppressing contractile amplitude ($P < 0.001$).

Effect of EP₂ Agonists on 5-HT-Induced and Spontaneous Myometrial Activity. The EP₂ agonist butaprost did not inhibit 5-HT-induced myogenicity in nongestational and gestational mouse tissues or spontaneous contractions in uterine strips taken during labor (Fig. 3A). Similarly, the nonprostanoid EP₂ agonist CP533536 had no effect on 5-HT-driven activity in tissues taken on day 18 of gestation. In tissues taken during dioestrus and labor, CP533536 attenuated both 5-HT-induced and spontaneous myometrial contractions by 52% and 83%, respectively ($P < 0.05$).

In immersed lower segment myometrium from nonpregnant and pregnant women, both butaprost and CP533536 caused a gradual decline in contractility compared with vehicle ($P < 0.01$ to $P < 0.001$; Fig. 3B). Potency values were similar for both EP₂ mimetics (pEC₅₀: 6.7 ± 0.4 and 6.5 ± 0.5 M, respectively). Complete cessation of activity was achieved in many tissue strips at 10⁻⁵ M, especially when taken during labor.

Effect of EP₄ Agonists on 5-HT-Induced and Spontaneous Myometrial Activity. The EP₄ agonists evoked dose-dependent inhibition of 5-HT-induced myogenicity in mouse tissues obtained in the nongravid state ($P < 0.01$; Fig. 4A), with L-902688 more potent than LAC-PGE. In gestational uteri, L-902688 had no effect on 5-HT or spontaneously driven uterine contractions. However, bolus doses of LAC-PGE produced a biphasic excitatory response followed by a period of inhibition. When compared with vehicle, LAC-PGE enhanced contractility in tissues taken on day 18 of gestation ($P < 0.05$).

The concentration-effect curves for LAC-PGE and L-902688 exhibited different responses in isolated human myometrium. When taken during the follicular phase, both EP₄ agonists gradually reduced myogenic activity compared with time-matched vehicles ($P < 0.05$ to $P < 0.001$); at 10⁻⁶ M, responses to LAC-PGE plateaued (Fig. 4B). LAC-PGE induced a similar biphasic response at term pregnancy ($P < 0.05$) but not during labor. Despite a decrease at 10⁻⁵ M, L-902688 had no significant effect on myometrial tonus or contractility.

Effect of EP_{1/3} Agonists on Myometrial Activity. The EP_{3/1} agonist sulprostone and EP₁ agonist ONO-D1-004 evoked excitation in all murine tissues. Sulprostone produced greater contractile effects than both ONO-D1-004 ($P < 0.05$ to $P < 0.01$) and PGE₂ ($P < 0.05$ to $P < 0.01$) in nonpregnant tissues (Fig. 5A). In uterine tissue taken on day 18 of gestation and during labor, PGE₂ and sulprostone were more potent than ONO-D1-004 ($P < 0.05$ to $P < 0.001$). The excitatory effects of sulprostone and ONO-D1-004 were higher in gestational over nongestational tissues.

In myometrium from nonpregnant, term pregnant, and laboring women, ONO-D1-004 had no effect on phasic contractions (Fig. 5B). Sulprostone evoked excitatory responses compared with ONO-D1-004 and PGE₂ ($P < 0.01$ to $P < 0.001$). The induced rise in activity compared with vehicle (12.5%, 9.4%, and 12.6%, respectively) corresponded to intensified frequency and amplitude of contractions.




Fig. 1. Dose-response curves (10^{-11} – 10^{-7} mol) and typical traces for PGE₂ in (A) upper and (B) lower segments of mouse uterine horn. Matching tissues were obtained from nonpregnant ($n = 6$), pregnant (gestation day 18; $n = 7$), and laboring mice ($n = 8$). Tissue strips were superfused with Krebs' solution. Activity was determined over 5-minute periods (area under the curve) and expressed as percentage of a reference contraction induced by hypotonic shock. Data are expressed as arithmetic means \pm S.E.M., and statistical significance was determined by two-way ANOVA with Tukey's *post hoc* test. $**P < 0.01$; $***P < 0.001$ for nonpregnant compared with gestation day 18; $^{\dagger}P < 0.05$; $^{\dagger\dagger}P < 0.01$; $^{\dagger\dagger\dagger}P < 0.001$ for nonpregnant compared with labor; $^{\#}P < 0.05$ for gestation day 18 compared with labor.

Abundance and Distribution of EP Receptors in Mouse Uterus. Gene expression of each EP receptor transcript was equivalent in upper and lower regions of the isolated nonpregnant, term pregnant, and laboring mouse uterus (Fig. 6). Detection of EP₁ mRNA was relatively low but peaked at term pregnancy compared with tissues taken at dioestrus ($P < 0.01$) and during labor ($P < 0.05$). In contrast, abundant EP₃ compliments were notable in all uterine samples, especially in the nonpregnant uterus. Relative EP₃ expression decreased with advancing gestation ($P < 0.001$); interestingly, this was not consistent with its contractile effects (Fig. 5A). A reduction in EP₂ ($P < 0.01$) and EP₄ ($P < 0.05$) receptors was also observed in gestational tissues, better reflecting their agonist-induced effects (Fig. 3A; Fig. 4A).

Discussion

These studies confirm the presence of a functionally heterogeneous EP receptor population in mouse and human uteri, which was characterized for the first time across gestational states. It was discovered that EP₃-mediated excitation predominates with uterotonic effects enhanced in the late

gestational and laboring uterus, indicating the EP₃ receptor as a therapeutic target in women's reproductive health.

PGE₂ has previously been shown to exhibit diverse effects on smooth muscle contractility via EP₁₋₄ subtypes (Coleman et al., 1994). In this study, EP receptor agonist effects varied according to hormonal milieu, most likely because of the differential regulation of EP₃ receptors that play an important role in the labor process. Limited EP₂ receptor agonist function in mouse but not human tissues substantiate previous findings that murine EP₂ mRNA was localized to luminal epithelial cells rather than uterine myocytes (Lim and Dey, 1997; Yang et al., 1997). This suggests that changes in the spatial and temporal expression of EP receptors may mediate uterine events during the oestrous and menstrual cycle, pregnancy, and parturition.

Maintained excitatory response to PGE₂ along the length of the mouse uterine horn reflects the relatively uniform EP receptor complements in nongestational and gestational tissues. However, in human myometrium, the expression and ratio of EP subtypes were shown to differ. While the expression of EP₁ and EP₄ transcripts remain constant throughout the uterus, EP₂ receptors increased toward the




Fig. 2. Concentration-effect curves (10^{-10} – 10^{-5} M) and typical traces for PGE₂ in isolated lower segment myometrium obtained from nonpregnant ($n = 11$), term pregnant, not in labor ($n = 6$), and laboring women ($n = 4$). Tissue strips were immersed in Krebs' solution. Activity was determined over 30-minute periods (area under the curve) and expressed as percentage of a reference contraction induced by hypotonic shock. Data are shown as arithmetic means \pm S.E.M., and statistical significance was determined by two-way ANOVA with Tukey's *post hoc* test. * $P < 0.05$; ** $P < 0.01$ for nonpregnant compared with term pregnant; † $P < 0.05$; ††† $P < 0.001$ for nonpregnant compared with labor; ## $P < 0.01$; ### $P < 0.001$ for term pregnant compared with labor.

cervix, whereas EP₃ receptors were reported to be the same (Arulkumaran et al., 2012) or more abundant in the upper uterine segment (Astle et al., 2005; Grigsby et al., 2006). Predominant PGE₂ tissue excitation in the mouse uterus is likely to represent upper segment function in women. In litter-bearing mice, this may indicate its role to deliver multiple fetuses. It is possible that the uterine body distal to the uterine horns is more translational to the lower segment in women. The clinical implications of sampling upper uterine tissue and ethical restrictions limiting sampling to the lower human uterus prevented the investigation of regional differences.

Because of the decline in spontaneous activity in myometrial strips obtained from nonpregnant and pregnant (gestation day 18) mice (Griffiths, 2007), 5-HT was used to drive *in vitro* phasic contractions. The biphasic response to PGE₂ observed in the 5-HT-induced nongravid tissues indicated the presence of both inhibitory and excitatory EP receptors. These findings were supported by functional studies using the isolated porcine (Cao et al., 2005) and human uterus (Senior et al., 1991).

To identify the functional population of inhibitory EP receptors, selective EP₂ and EP₄ agonists were used in this study. The EP₂ agonists butaprost (Gardiner, 1986) and CP533536 (Li et al., 2003; Paralkar et al., 2003) are well

documented for high selectivity at the EP₂ receptor with respective K_i values of 110 and 50 nM (Kiriyama et al., 1997; Li et al., 2003; Paralkar et al., 2003). Even so, butaprost showed no significant effects in mice, while CP533536 only attenuated myometrial activity at the highest dose. This suggests a paucity of functional uterine EP₂ receptors, which corresponded to findings in the guinea pig (Lebel et al., 2004). However, EP₂ mRNA expression was shown to increase during pregnancy and decline at term labor in the rat uterus (Brodt-Eppley and Myatt, 1998; Dong and Yallampalli, 2000). Furthermore, in isolated human myometrium, responsiveness to PGE₂ is thought to be primarily mediated via the EP₂ receptor (Senior et al., 1991; Senior et al., 1993; Duckworth et al., 2002; Fischer et al., 2008) and cAMP signaling (Sooranna et al., 2005), with its expression altered in a temporal and regional manner. Myometrial EP₂ receptors decrease toward term gestation (Matsumoto et al., 1997; Brodt-Eppley and Myatt, 1999; Leonhardt et al., 2003) and are reported to not change (Dong and Yallampalli, 2000; Lebel et al., 2004; Kandola et al., 2014) or increase during parturition (Grigsby et al., 2006). The expression of EP₂ receptors is also more intense in the lower rather than upper human uterine segments (Astle et al., 2005; Grigsby et al., 2006). This may explain similar EP₂-mediated effects in this study, contributing to the relaxant




Fig. 3. Vehicle and dose-response curves for EP₂ receptor agonists butaprost and CP533536 in uterine samples taken from (A) mice at (i) dioestrus ($n = 6$), (ii) gestation day 18 ($n = 6-8$), and (iii) during labor ($n = 3-5$) as well as from (B) human donors in (i) the follicular phase ($n = 6-9$), (ii) term pregnancy ($n = 6$), and (iii) during labor ($n = 4-6$). Upper segment uteri from mice were superfused, and lower myometrial biopsies from women were immersed in Krebs' solution. Responses are shown as percentage of a reference contraction induced by hypotonic shock. Data are expressed as arithmetic mean \pm S.E.M., and statistical significance was determined by two-way ANOVA with Tukey's *post hoc* test. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$ for vehicle compared with butaprost; †† $P < 0.01$; ††† $P < 0.001$ for vehicle compared with CP533536.

phenotype of the lower uterus during parturition for successful neonatal delivery.

In contrast, EP₄ receptors in mouse uterus showed gestational but not regional-related changes. The pharmacological effects of LAC-PGE and L-902688 diminished during pregnancy and labor, following the EP₄ expression profile. At term gestation, tissue excitation evoked by LAC-PGE may be attributed to off-target activation of EP₃ receptors (Maruyama et al., 2001). L-902688 produced the greatest inhibition and was reported to be 3 to 5 times more potent than PGE₂ (Billot et al., 2003). EP₄ receptors were also consistently expressed in

human uterus (Astle et al., 2005; Grigsby et al., 2006) and were reported to have a negligible function (Hillock and Crankshaw, 1999). The LAC-PGE analog used in this study displayed utero-relaxant effects, possibly because of its high affinity and 1000-fold subtype selectivity for EP₄ (Ki: 4.5 nM) (Elworthy et al., 2004) compared with the previously studied EP₄ receptor antagonist AH23848B (Ki: 2690 nM) (Davis and Sharif, 2000). Even so, efficacy was low, especially at term gestation and labor, substantiating that inhibitory receptors are predominantly of the EP₂ subtype. Because of its involvement in cervical ripening (Schmitz et al., 2001), EP₄




Fig. 4. Vehicle and dose-response curves for EP₄ receptor agonists LAC-PGE and L-902688 in uterine samples taken from (A) mice at (i) dioestrus ($n = 6$), (ii) gestation day 18 ($n = 6-7$), and (iii) during labor ($n = 3-4$) as well as from (B) human donors in (i) the follicular phase ($n = 3-7$), (ii) term pregnancy ($n = 3-6$), and (iii) during labor ($n = 3-5$). Upper segment uteri from mice were superfused, and lower myometrial biopsies from women were immersed in Krebs' solution. Responses are shown as percentage of a reference contraction induced by hypotonic shock. Data are expressed as arithmetic mean \pm S.E.M., and statistical significance was determined by two-way ANOVA with Tukey's *post hoc* test. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$ for vehicle compared with LAC-PGE; † $P < 0.05$; †† $P < 0.01$ for vehicle compared with L-902688; # $P < 0.05$ for LAC-PGE compared with L-902688.

receptors may have a distinct role from modulating uterine contractions in mouse and human uteri at term.

Despite predominant human uterine quiescence, responses evoked by PGE₂ suggest the presence of contractile EP receptor subtypes in all tissue types. EP₃ receptor mRNA is highly expressed in the mouse uterus (Sugimoto et al., 1992) and has been detected on uterine smooth muscle cells (Katsuyama et al., 1997; Yang et al., 1997). However, there are conflicting reports concerning the EP₁ subtype with either

low (Yang et al., 1997) or undetectable levels of mRNA identified (Katsuyama et al., 1997), perhaps relating to the nuclear sequestration of EP₁ during labor (Arulkumaran et al., 2012). ONO-D1-004, which is a specific EP₁ agonist, has been shown to be eightfold less potent than PGE₂ (Oka et al., 2003). Nevertheless, in this study, PGE₂ and ONO-D1-004 evoked analogous uterotonic responses in isolated tissue from non-pregnant animals. Sulprostone, an EP_{3/1} agonist, augmented uterine contractility, indicating EP₁ and EP₃ receptor function.




Fig. 5. Dose-response curves for PGE₂, the EP_{3/1} receptor agonist sulprostone and the EP₁ receptor agonist ONO-D1-004 in uterine samples taken from (A) mice at (i) dioestrus ($n = 11-12$), (ii) gestation day 18 ($n = 5-7$), and (iii) during labor ($n = 3-7$). Upper segment uteri from mice were superfused, and lower myometrial biopsies from women were immersed in Krebs' solution. Responses are shown as percentage of a reference contraction induced by hypotonic shock. Data are expressed as arithmetic mean \pm S.E.M., and statistical significance was determined by two-way ANOVA with Bonferroni's *post hoc* test. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$ for PGE₂ compared with sulprostone; † $P < 0.05$; †† $P < 0.01$; ††† $P < 0.001$ for sulprostone compared with ONO-D1-004; # $P < 0.05$; ## $P < 0.01$; ### $P < 0.001$ for PGE₂ compared with ONO-D1-004.

Given that PGE₂ binds to its receptor subtypes with a rank order of affinity of EP₃ > EP₄ > EP₂ > EP₁ (Kiriya et al., 1997), its contractile effects may have been moderated by its actions on inhibitory EP receptors. Even so, unlike the hypothesis, EP₃ receptors appear to have a greater role.

In mice, tissue excitation was upregulated in late gestational compared with nongestational tissues. While overall expression was lower, proportionally EP₃ receptors were threefold higher than EP₂ and EP₄ subtypes at term pregnancy and labor than in the nonpregnant uterus. Because of the excitatory profile maintained during labor, it is likely that

EP₃ receptors are involved in the contractile force associated with parturition. In human, baboon, and guinea-pig myometrium at term pregnancy and labor, EP₃ receptor expression was similarly reported to be greater than that of EP₂ and EP₄ receptors (Matsumoto et al., 1997; Smith et al., 2001; Terry et al., 2008). This provides support to exploit EP₃ receptors as a potential target for tocolysis or improved labor induction. Antagonizing EP₃ receptors also shows pharmacological promise through their apparent antithrombotic and antiulcer effects, which are currently under clinical evaluation (Marković et al., 2017; Xiang et al., 2019).




Fig. 6. Expression of (A) EP₁, (B) EP₂, (C) EP₃, and (D) EP₄ transcripts in upper and lower mouse uterus taken at dioestrus (NP; $n = 5$), term gestation day 18 (P; $n = 5$), and during labor (L; $n = 5$). Total RNA was extracted using the TRIzol method and quantified using real-time reverse-transcription PCR, and gene expression was normalized against β -actin and GAPDH relative to an internal control. Data are shown as the median and interquartile range and analyzed using a Friedman's two-way ANOVA with Dunn's multiple comparisons *post hoc* test; * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$ for upper and †† $P < 0.01$ for lower uterus from non-pregnant mice compared with gestational tissues; and # $P < 0.05$ for upper and * $P < 0.05$ for lower uterus from gestation day 18 mice compared with laboring tissues.

In conclusion, a heterogeneous EP receptor population characterized in mouse and human female reproductive tracts showed some similarities. In lower segment nongestational tissues, both EP₄ and EP₂ receptor agonists suppressed uterine activity without affecting resting tone. Their contrasting tocolytic potential at term pregnancy perhaps reflected uterine topography. In all tissues, EP₃-mediated excitation seemed to predominate with uterotonic effects enhanced in the late gestational and laboring uterus. These findings support development of new selective EP₃ receptor modalities, which are currently being investigated for local drug delivery. Examining their effects in mice offers valuable preclinical insight that could be used to improve response rates for labor induction or as a therapy for menstrual cramps, pelvic pain, or preterm labor caused by uterine hypercontractility.

Acknowledgments

The authors would like to thank Allergan Inc. for their generous supply of compounds and for supporting D.P.F., A.L.G., and U.J.S.

Authorship Contributions

Participated in research design: Fischer, Griffiths, Lui, Woodward, Marshall.

Conducted experiments: Fischer, Griffiths, Lui.

Contributed new reagents or analytical tools: Woodward, Marshall.

Performed data analysis: Fischer, Griffiths.

Wrote or contributed to the writing of the manuscript: Fischer, Griffiths, Sabar, Farrar, O'Donovan, Woodward, Marshall.

References

- Arulkumaran S, Kandola MK, Hoffman B, Hanyaloglu AC, Johnson MR, and Bennett PR (2012) The roles of prostaglandin EP 1 and 3 receptors in the control of human myometrial contractility. *J Clin Endocrinol Metab* **97**:489–498.
- Astle S, Thornton S, and Slater DM (2005) Identification and localization of prostaglandin E₂ receptors in upper and lower segment human myometrium during pregnancy. *Mol Hum Reprod* **11**:279–287.
- Billot X, Chateaufauf A, Chaurat N, Denis D, Greig G, Mathieu MC, Metters KM, Slipetz DM, and Young RN (2003) Discovery of a potent and selective agonist of the prostaglandin EP4 receptor. *Bioorg Med Chem Lett* **13**:1129–1132.

- Brodts-Eppley J and Myatt L (1998) Changes in expression of contractile FP and relaxatory EP2 receptors in pregnant rat myometrium during late gestation, at labor, and postpartum. *Biol Reprod* **59**:878–883.
- Brodts-Eppley J and Myatt L (1999) Prostaglandin receptors in lower segment myometrium during gestation and labor. *Obstet Gynecol* **93**:89–93.
- Calder AA (1990) Prostaglandins as therapy for labour induction or therapeutic abortion. *Reprod Fertil Dev* **2**:553–556.
- Cao J, Yosida M, Kitazawa T, and Taneike T (2005) Uterine region-dependent differences in responsiveness to prostaglandins in the non-pregnant porcine myometrium. *Prostaglandins Other Lipid Mediat* **75**:105–122.
- Challis JR, Sloboda DM, Alfaidy N, Lye SJ, Gibb W, Patel FA, Whittle WL, and Newnham JP (2002) Prostaglandins and mechanisms of preterm birth. *Reproduction* **124**:1–17.
- Coleman RA, Smith WL, and Narumiya S (1994) International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. *Pharmacol Rev* **46**:205–229.
- Davis TL and Sharif NA (2000) Pharmacological characterization of [³H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor. *Br J Pharmacol* **130**:1919–1926.
- Dong YL and Yallampalli C (2000) Pregnancy and exogenous steroid treatments modulate the expression of relaxant EP(2) and contractile FP receptors in the rat uterus. *Biol Reprod* **62**:533–539.
- Duckworth N, Marshall K, and Clayton JK (2002) An investigation of the effect of the prostaglandin EP2 receptor agonist, butaprost, on the human isolated myometrium from pregnant and non-pregnant women. *J Endocrinol* **172**:263–269.
- Durm JH, Marshall KM, Farrar D, O'Donovan P, Scally AJ, Woodward DF, and Nicolaou A (2010) Lipidomic analysis reveals prostanoid profiles in human term pregnant myometrium. *Prostaglandins Leukot Essent Fatty Acids* **82**:21–26.
- Elworthy TR, Kertesz DJ, Kim W, Roepel MG, Quattrocchio-Setti L, Smith DB, Tracy JL, Chow A, Li F, Brill ER, et al. (2004) Lactams as EP4 prostanoid receptor subtype selective agonists. Part 1: 2-Pyrrolidinones-stereochemical and lower side-chain optimization. *Bioorg Med Chem Lett* **14**:1655–1659.
- Fischer DP, Hutchinson JA, Farrar D, O'Donovan PJ, Woodward DF, and Marshall KM (2008) Loss of prostaglandin F_{2alpha}, but not thromboxane, responsiveness in pregnant human myometrium during labor. *J Endocrinol* **197**:171–179.
- Gardiner PJ (1986) Characterization of prostanoid relaxant/inhibitory receptors (psi) using a highly selective agonist, TR4979. *Br J Pharmacol* **87**:45–56.
- Gouveia-Figueira S, Martens DS, Nawrot TS, and Nording ML (2017) Cord blood eicosanoid signatures and newborn gestational age. *Prostaglandins Other Lipid Mediat* **133**:123–127.
- Griffiths AL (2007) The influence of the hormonal milieu on uterine prostaglandin EP, FP and TP-receptor populations. PhD Thesis, University of Bradford.
- Griffiths AL, Marshall KM, Senior J, Fleming C, and Woodward DF (2006) Effect of the oestrous cycle, pregnancy and uterine region on the responsiveness of the isolated mouse uterus to prostaglandin F(2alpha) and the thromboxane mimetic U46619. *J Endocrinol* **188**:569–577.
- Grigsby PL, Sooranna SR, Adu-Amankwa B, Pitzer B, Brockman DE, Johnson MR, and Myatt L (2006) Regional expression of prostaglandin E₂ and F_{2alpha} receptors in human myometrium, amnion, and choriondecidua with advancing gestation and labor. *Biol Reprod* **75**:297–305.
- Hedegaard M, Lidgaard Ø, Skovlund CW, Mørch LS, and Hedegaard M (2014) Reduction in stillbirths at term after new birth induction paradigm: results of a national intervention. *BMJ Open* **4**:e005785.

- Hillock CJ and Crankshaw DJ (1999) Inhibitory prostanoid EP receptors in human non-pregnant myometrium. *Eur J Pharmacol* **378**:99–108.
- Hizaki H, Segi E, Sugimoto Y, Hirose M, Saji T, Ushikubi F, Matsuoka T, Noda Y, Tanaka T, Yoshida N, et al. (1999) Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP(2). *Proc Natl Acad Sci USA* **96**:10501–10506.
- Hla T (2005) Genomic insights into mediator lipidomics. *Prostaglandins Other Lipid Mediat* **77**:197–209.
- Honda A, Sugimoto Y, Namba T, Watabe A, Irie A, Negishi M, Narumiya S, and Ichikawa A (1993) Cloning and expression of a cDNA for mouse prostaglandin E receptor EP2 subtype. *J Biol Chem* **268**:7759–7762.
- Kandola MK, Sykes L, Lee YS, Johnson MR, Hanyaloglu AC, and Bennett PR (2014) EP2 receptor activates dual G protein signaling pathways that mediate contrasting proinflammatory and relaxatory responses in term pregnant human myometrium. *Endocrinology* **155**:605–617.
- Katsuyama M, Sugimoto Y, Morimoto K, Hasumoto K, Fukumoto M, Negishi M, and Ichikawa A (1997) 'Distinct cellular localization' of the messenger ribonucleic acid for prostaglandin E receptor subtypes in the mouse uterus during pseudo-pregnancy. *Endocrinology* **138**:344–350.
- Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, Magnuson MA, Oates JA, Breyer MD, and Breyer RM (1999) Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. *Nat Med* **5**:217–220.
- Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, and Narumiya S (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. *Br J Pharmacol* **122**:217–224.
- Konopka CK, Glanzner WG, Rigo ML, Rovani MT, Comin FV, Gonçalves PB, Morais EN, Antoniazzi AQ, Mello CF, and Cruz IB (2015) Responsivity to PGE2 labor induction involves concomitant differential prostaglandin E receptor gene expression in cervix and myometrium. *Genet Mol Res* **14**:10877–10887.
- Lebel W, Riccardi K, Grasser WA, Terry K, Thompson D, and Paralkar VM (2004) Prostaglandin E2 receptor subtype EP-2 is not involved in the induction of non-pregnant guinea pig uterine contractions associated with terminal pregnancy. *Prostaglandins Leukot Essent Fatty Acids* **71**:399–404.
- Lee SE, Romero R, Park IS, Seong HS, Park CW, and Yoon BH (2008) Amniotic fluid prostaglandin concentrations increase before the onset of spontaneous labor at term. *J Matern Fetal Neonatal Med* **21**:89–94.
- Leonhardt A, Glaser A, Wegmann M, Hackenberg R, and Nüsing RM (2003) Expression of prostanoid receptors in human lower segment pregnant myometrium. *Prostaglandins Leukot Essent Fatty Acids* **69**:307–313.
- Li M, Ke HZ, Qi H, Healy DR, Li Y, Crawford DT, Paralkar VM, Owen TA, Cameron KO, Lefker BA, et al. (2003) A novel, non-prostanoid EP2 receptor-selective prostaglandin E2 agonist stimulates local bone formation and enhances fracture healing. *J Bone Miner Res* **18**:2033–2042.
- Lim H and Dey SK (1997) Prostaglandin E2 receptor subtype EP2 gene expression in the mouse uterus coincides with differentiation of the luminal epithelium for implantation. *Endocrinology* **138**:4599–4606.
- Lu JW, Wang WS, Zhou Q, Gan XW, Myatt L, and Sun K (2019) Activation of prostaglandin EP4 receptor attenuates the induction of cyclooxygenase-2 expression by EP2 receptor activation in human amnion fibroblasts: implications for parturition. *FASEB J* **33**:8148–8160.
- Marković T, Jakopin Ž, Dolenc MS, and Mlinarič-Rašcan I (2017) Structural features of subtype-selective EP receptor modulators. *Drug Discov Today* **22**:57–71.
- Maruyama T, Asada M, Shiraiishi T, Ishida A, Egashira H, Yoshida H, Maruyama T, Ohuchida S, Nakai H, Kondo K, et al. (2001) Design and synthesis of a highly selective EP4-receptor agonist. Part 1: 3,7-dithiapyridine derivatives with high selectivity. *Bioorg Med Chem Lett* **11**:2029–2031.
- Matsumoto T, Sagawa N, Yoshida M, Mori T, Tanaka I, Mukoyama M, Kotani M, and Nakao K (1997) The prostaglandin E2 and F2_{alpha} receptor genes are expressed in human myometrium and are down-regulated during pregnancy. *Biochem Biophys Res Commun* **238**:838–841.
- Matsuoka T and Narumiya S (2007) Prostaglandin receptor signaling in disease. *ScientificWorldJournal* **7**:1329–1347.
- McLean AC, Valenzuela N, Fai S, and Bennett SA (2012) Performing vaginal lavage, crystal violet staining, and vaginal cytological evaluation for mouse estrous cycle staging identification. *J Vis Exp* e4389.
- NICE (2008) *Induction of Labour*, p 124, National Collaborating Centre for Women's and Children's Health London, UK.
- Nishigaki N, Negishi M, Honda A, Sugimoto Y, Namba T, Narumiya S, and Ichikawa A (1995) Identification of prostaglandin E receptor 'EP2' cloned from mastocytoma cells EP4 subtype. *FEBS Lett* **364**:339–341.
- Oka T, Oka K, and Saper CB (2003) Contrasting effects of E type prostaglandin (EP) receptor agonists on core body temperature in rats. *Brain Res* **968**:256–262.
- Paralkar VM, Borovecki F, Ke HZ, Cameron KO, Lefker B, Grasser WA, Owen TA, Li M, DaSilva-Jardine P, Zhou M, et al. (2003) An EP2 receptor-selective prostaglandin E2 agonist induces bone healing. *Proc Natl Acad Sci USA* **100**:6736–6740.
- Popat A and Crankshaw DJ (2001) Variable responses to prostaglandin E(2) in human non-pregnant myometrium. *Eur J Pharmacol* **416**:145–152.
- Ruan YC, Guo JH, Liu X, Zhang R, Tsang LL, Dong JD, Chen H, Yu MK, Jiang X, Zhang XH, et al. (2012) Activation of the epithelial Na⁺ channel triggers prostaglandin E2 release and production required for embryo implantation. *Nat Med* **18**:1112–1117.
- Schaaf TK, Bindra JS, Egger JF, Plattner JJ, Nelson AJ, Johnson MR, Constantine JW, Hess HJ, and Elger W (1981) N-(Methanesulfonyl)-16-phenoxyprostaglandin-carboxamides: tissue-selective, uterine stimulants. *J Med Chem* **24**:1353–1359.
- Schmitz T, Dallot E, Leroy MJ, Breuille-Fouché M, Ferré F, and Cabrol D (2001) EP(4) receptors mediate prostaglandin E(2)-stimulated glycosaminoglycan synthesis in human cervical fibroblasts in culture. *Mol Hum Reprod* **7**:397–402.
- Senior J, Marshall K, Sangha R, Baxter GS, and Clayton JK (1991) In vitro characterization of prostanoid EP-receptors in the non-pregnant human myometrium. *Br J Pharmacol* **102**:747–753.
- Senior J, Marshall K, Sangha R, and Clayton JK (1993) In vitro characterization of prostanoid receptors on human myometrium at term pregnancy. *Br J Pharmacol* **108**:501–506.
- Sheibani L, Raymond K, Rugarn O, and Wing DA (2018) Associations of hypertensive disorders of pregnancy and outcomes of labor induction with prostaglandin vaginal inserts. *Hypertens Pregnancy* **37**:51–57.
- Smith GC, Wu WX, and Nathanielsz PW (2001) Effects of gestational age and labor on expression of prostanoid receptor genes in baboon uterus. *Biol Reprod* **64**:1131–1137.
- Sooranna SR, Grigsby P, Myatt L, Bennett PR, and Johnson MR (2005) Prostanoid receptors in human uterine myocytes: the effect of reproductive state and stretch. *Mol Hum Reprod* **11**:859–864.
- Sugimoto Y, Namba T, Honda A, Hayashi Y, Negishi M, Ichikawa A, and Narumiya S (1992) Cloning and expression of a cDNA for mouse prostaglandin E receptor EP3 subtype. *J Biol Chem* **267**:6463–6466.
- Sugimoto Y and Narumiya S (2007) Prostaglandin E receptors. *J Biol Chem* **282**:11613–11617.
- Terry KK, Lebel WS, Riccardi KA, Grasser WA, Thompson DD, and Paralkar VM (2008) Effects of gestational age on prostaglandin EP receptor expression and functional involvement during in vitro contraction of the guinea pig uterus. *Prostaglandins Leukot Essent Fatty Acids* **78**:3–10.
- Tilley SL, Audoly LP, Hicks EH, Kim HS, Flannery PJ, Coffman TM, and Koller BH (1999) Reproductive failure and reduced blood pressure in mice lacking the EP2 prostaglandin E2 receptor. *J Clin Invest* **103**:1539–1545.
- Valdes G, Kaufmann P, Corthorn J, Ericas R, Brosnihan KB, and Joyner-Grantham J (2009) Vasodilator factors in the systemic and local adaptations to pregnancy. *Reprod Biol Endocrinol* **7**:79.
- Vogel JP, Osoti AO, Kelly AJ, Livio S, Norman JE, and Alfirevic Z (2017) Pharmacological and mechanical interventions for labour induction in outpatient settings. *Cochrane Database Syst Rev* **9**:CD007701.
- Watabe A, Sugimoto Y, Honda A, Irie A, Namba T, Negishi M, Ito S, Narumiya S, and Ichikawa A (1993) Cloning and expression of cDNA for a mouse EP1 subtype of prostaglandin E receptor. *J Biol Chem* **268**:20175–20178.
- Xiang Q, Pang X, Liu Z, Yang G, Tao W, Pei Q, and Cui Y (2019) Progress in the development of antiplatelet agents: focus on the targeted molecular pathway from bench to clinic. *Pharmacol Ther* **203**:107393.
- Yang ZM, Das SK, Wang J, Sugimoto Y, Ichikawa A, and Dey SK (1997) Potential sites of prostaglandin actions in the periimplantation mouse uterus: differential expression and regulation of prostaglandin receptor genes. *Biol Reprod* **56**:368–379.
- Zhao L, Lin Y, Jiang TT, Wang L, Li M, Wang Y, Sun GQ, and Xiao M (2019) Vaginal delivery among women who underwent labor induction with vaginal dinoprostone (PGE2) insert: a retrospective study of 1656 women in China. *Pharmacol Ther* **32**:1721–1727.

Address correspondence to: Deborah P. Fischer, Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester M13 9PL, United Kingdom. E-mail: debbie.fischer@manchester.ac.uk